HIK.L

Hikma Pharmaceuticals Plc
Hikma Pharmaceutical - Outcome of Audit Tender Process
7th November 2024, 15:30
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 4195L
Hikma Pharmaceuticals Plc
07 November 2024
 

Hikma Pharmaceuticals PLC

Outcome of Audit Tender Process

 

LONDON, 7 November 2024 - Hikma Pharmaceuticals PLC ('the Company' or 'Hikma') announces that, following the completion of a formal competitive audit tender process, the Board of Directors has approved the reappointment of PricewaterhouseCoopers LLP ('PwC') as the external auditor of Hikma from 2026 onwards. 

As a UK public interest entity, Hikma is required to carry out an audit tender every 10 years and rotate the external auditor every 20 years. We disclosed in our 2023 Annual Report & Accounts the intention to commence an audit tender, given PwC were initially appointed for the audit of the 2016 Annual Report & Accounts.

Further details of the audit tender process will be included in our 2024 Annual Report & Accounts. This appointment is subject to shareholder approval at the 2026 Annual General Meeting.

 

- ENDS -

Enquiries

 

Hikma Pharmaceuticals PLC

 
 

Helen Middlemist

Group Company Secretary

+44 20 7399 2760

 

About Hikma

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,100 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)

(LEI: 549300BNS685UXH4JI75)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUBUVRSBUARAA]]>
TwitterFacebookLinkedIn